GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » PB Ratio

Marker Therapeutics (FRA:GX1) PB Ratio : 1.33 (As of Apr. 03, 2025)


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-03), Marker Therapeutics's share price is €1.00. Marker Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was €0.75. Hence, Marker Therapeutics's PB Ratio of today is 1.33.

Warning Sign:

Marker Therapeutics Inc stock PB Ratio (=1.37) is close to 3-year high of 1.37.

The historical rank and industry rank for Marker Therapeutics's PB Ratio or its related term are showing as below:

FRA:GX1' s PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 2.34   Max: 184.2
Current: 1.37

During the past 13 years, Marker Therapeutics's highest PB Ratio was 184.20. The lowest was 0.11. And the median was 2.34.

FRA:GX1's PB Ratio is ranked better than
66.87% of 1283 companies
in the Biotechnology industry
Industry Median: 2.22 vs FRA:GX1: 1.37

During the past 12 months, Marker Therapeutics's average Book Value Per Share Growth Rate was -56.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -34.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Marker Therapeutics was 80.90% per year. The lowest was -68.70% per year. And the median was 9.50% per year.

Back to Basics: PB Ratio


Marker Therapeutics PB Ratio Historical Data

The historical data trend for Marker Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics PB Ratio Chart

Marker Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.10 2.69 1.76 0.96 1.94

Marker Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.94 3.27 4.32 3.24

Competitive Comparison of Marker Therapeutics's PB Ratio

For the Biotechnology subindustry, Marker Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marker Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's PB Ratio falls into.


;
;

Marker Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Marker Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.00/0.752
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Marker Therapeutics  (FRA:GX1) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Marker Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Marker Therapeutics Business Description

Traded in Other Exchanges
Address
9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics Headlines

No Headlines